| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | KH-CB19 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.0094 | 0.8 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | 0.017 | 0.8 |
| mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | 0.0083 | 0.8 |